[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-335197-105":59,"doc-detail-335197-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","novel-potent-molecular-glue-degraders-against-broad-range-of-hematological-cancer-cell-lines-via-multiple-neosubstrates-degradation","Novel potent molecular glue degraders against broad range of hematological cancer cell lines via multiple neosubstrates degradation","","Targeted protein degradation of neosubstrates is central to immunomodulatory imide drug (IMiD) therapy in hematological cancers, yet clinical translation is hindered by persistent drug resistance and hematological toxicities. This study performs phenotypic profiling across multiple cell lines to identify lead degraders, then applies molecular-dynamics–guided rational design and functional assays to improve potency. Xenograft and patient-derived models evaluate antitumor efficacy, while unbiased proteomics and RT-PCR clarify therapeutically relevant neosubstrates and IMiD resistance mechanisms, including BRD9 involvement.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/novel-potent-molecular-glue-degraders-against-broad-range-of-hematological-cancer-cell-lines-via-multiple-neosubstrates-degradation/335197/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/novel-potent-molecular-glue-degraders-against-broad-range-of-hematological-cancer-cell-lines-via-multiple-neosubstrates-degradation/335197.png","ImageObject",300,407,{"name":92,"@type":93},"Asher","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-05","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What therapeutic problem does the study address regarding IMiDs in hematological cancers?","Question",{"text":112,"@type":113},"It targets limitations of IMiD-based neosubstrate degradation, especially inevitable drug resistance and hematological toxicities that reduce clinical effectiveness.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were potent molecular glue degraders identified and optimized in this work?",{"text":117,"@type":113},"Phenotypic profiling screened a compound library for hit degraders, followed by molecular-dynamics–based rational design and cell-based functional assays to develop more potent candidates.",{"name":119,"@type":110,"acceptedAnswer":120},"Which lead and candidate degrader molecules were reported, and what effects did they produce?",{"text":121,"@type":113},"The authors report a novel CRBN-dependent lead degrader, MGD-4, inducing degradation of Ikaros proteins, and a more potent candidate, MGD-28, which inhibited growth of cancer cells and promoted degradation of IKZF1/2/3 and CK1α with nanomolar potency.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},335197,1790638875,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":41,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":4},687197207639,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Li etal. Journal of Hematology & Oncology (2024) 17:77 [https://doi.org/10.1186/s13045-024-01592-z](https://doi.org/10.1186/s13045-024-01592-z)  \nJournal of Hematology & Oncology  \nRESEARCH Open Access  \nNovel potent molecular glue degraders against broad range of hematological cancer cell lines via multiple neosubstrates degradation  \nPengyun Li 1,2†, Xiaotong Hu 1,2†, Zhiya Fan3†, Shiyang Sun 1,2, Qijie Ran4,5, Ting Wei 1,2, Pengli Wei 1,2, Qiyu Jiang4, Jian Yan 1,2, Ning Yang 1,2, Changkai Jia 1,2, Tingting Yang6, Yaqiu Mao 1,2, Xu Cai 1,2, Tingting Xu 1,2, Zhiyuan Zhao 1,2, Xiaohong Qian3, Weijie Qin3, Xiaomei Zhuang2*, Feng Fan4*, Junhai Xiao 1,2*, Zhibing Zheng 1,2* and Song Li 1,2  \nAbstract  \nBackground Targeted protein degradation of neosubstrates plays a crucial role in hematological cancer treatment involving immunomodulatory imide drugs (IMiDs) therapy. Nevertheless, the persistence of inevitable drug resistance and hematological toxicities represents a significant obstacle to their clinical effectiveness.  \nMethods Phenotypic profiling of a small molecule compounds library in multiple hematological cancer cell lines was conducted to screen for hit degraders. Molecular dynamic-based rational design and cell-based functional assays were conducted to develop more potent degraders. Multiple myeloma (MM) tumor xenograft models were employed to investigate the antitumor efficacy of the degraders as single or combined agents with standard of care agents. Unbiased proteomics was employed to identify multiple therapeutically relevant neosubstrates targeted by the degraders. MM patient-derived cell lines (PDCs) and a panel of solid cancer cell lines were utilized to investigate the effects of candidate degrader on different stage of MM cells and solid malignancies. Unbiased proteomics of IMiDs-resistant MM cells, cell-based functional assays and RT-PCR analysis of clinical MM specimens were utilized to explore the role of BRD9 associated with IMiDs resistance and MM progression.  \nResults We identified a novel cereblon (CRBN)-dependent lead degrader with phthalazinone scaffold, MGD-4, which induced the degradation of Ikaros proteins. We further developed a novel potent candidate, MGD-28, significantly  \n†Pengyun Li, Xiaotong Hu and Zhiya Fan contributed equally to this work.  \n*Correspondence: Xiaomei Zhuang [xiaomeizhuang@163.com](xiaomeizhuang@163.com)[ ](xiaomeizhuang@163.com)Feng Fan [fengfanbio@126.com](fengfanbio@126.com)[ ](fengfanbio@126.com)Junhai Xiao [xiaojunhai@139.com](xiaojunhai@139.com)[ ](xiaojunhai@139.com)Zhibing Zheng [zzbcaptain@aliyun.com](zzbcaptain@aliyun.com)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2024. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://](http://)[ ](http://)[creativecommons.org/l](creativecommons.org/l)icenses/by-nc-nd/4.0/.  \nLi et al. Journal of Hematology & Oncology (2024) 17:77 Page 2 of 30  \ninhibited the growth of hematological cancer cells and induced the degradation of IKZF1/2/3 and CK1α with nanomolar potency vi","cbCaihNAf9AoEJMa","https://ap.wps.com/l/cbCaihNAf9AoEJMa","pdf",20090274,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusions\n# Keywords\n# Background","[{\"question\":\"What therapeutic problem does the study address regarding IMiDs in hematological cancers?\",\"answer\":\"It targets limitations of IMiD-based neosubstrate degradation, especially inevitable drug resistance and hematological toxicities that reduce clinical effectiveness.\"},{\"question\":\"How were potent molecular glue degraders identified and optimized in this work?\",\"answer\":\"Phenotypic profiling screened a compound library for hit degraders, followed by molecular-dynamics–based rational design and cell-based functional assays to develop more potent candidates.\"},{\"question\":\"Which lead and candidate degrader molecules were reported, and what effects did they produce?\",\"answer\":\"The authors report a novel CRBN-dependent lead degrader, MGD-4, inducing degradation of Ikaros proteins, and a more potent candidate, MGD-28, which inhibited growth of cancer cells and promoted degradation of IKZF1/2/3 and CK1α with nanomolar potency.\"}]","Novel potent molecular glue degraders against broad range of hematological cancer cell lines via multiple neosubstrates degradation | PDF",1790010080,76]